Sizable Layoffs Hit Four Life Science Companies

ALEX KEOWN | June 6, 2019

article image
Mid-year doldrums are hitting as multiple pharmaceutical and biotech companies have initiated layoffs across the United States. Last week, beleaguered Merrimack Pharmaceuticals announced it intended to lay off its entire staff, including its executive leadership, as the company is biding its time to receive milestone payments from Ipsen, related to the sale of some oncology assets, including pancreatic cancer drug Onivyde. The layoffs are the last for the company as it is now essentially closed. Cambridge, Mass.-based Merrimack sold off its last clinical-stage products and shuttered its preclinical development programs. A potential plan to rebuild will be announced at the company’s next annual meeting of shareholders, the board of directors said. Over the past few years, Merrimack had undergone a number of layoffs as the company struggled with its clinical programming, including the termination of 60% of its staff following the failure of a lung cancer trial.

Spotlight

Netcare

The Netcare Group operates the largest private hospital group, primary care network and medical emergency service in South Africa. Netcare is also the biggest private trainer of emergency personnel and healthcare workers. At Netcare, our inspiration to excel in providing medical innovation and quality care is to be found in our values. We continue to focus on living our core value of care, and the associated values of dignity, participation, truth and passion. Care at every level of our organisation is fundamental to Netcare's sustainability and our contribution to the countries in which we operate. It provides the reference point for all our people as we transform our businesses and seek to build bridges of trust with our patients, doctors and all other stakeholders.

OTHER ARTICLES
MEDICAL

Better Purification and Recovery in Bioprocessing

Article | August 2, 2021

In the downstream portion of any bioprocess, one must pick through the dross before one can seize the gold the biotherapeutic that the bioprocess was always meant to generate. Unfortunately, the dross is both voluminous and various. And the biotherapeutic gold, unlike real gold, is corruptible. That is, it can suffer structural damage and activity loss. When discarding the dross and collecting the gold, bioprocessors must be efficient and gentle. They must, to the extent possible, eliminate contaminants and organic debris while ensuring that biotherapeutics avoid aggregation-inducing stresses and retain their integrity during purification and recovery. Anything less compromises purity and reduces yield. To purify and recover biotherapeutics efficiently and gently, bioprocessors must avail themselves of the most appropriate tools and techniques. Here, we talk with several experts about which tools and techniques can help bioprocessors overcome persistent challenges. Some of these experts also touch on new approaches that can help bioprocessors address emerging challenges.

Read More
DIAGNOSTICS

Making Predictions by Digitizing Bioprocessing

Article | April 20, 2021

With advances in data analytics and machine learning, the move from descriptive and diagnostic analytics to predictive and prescriptive analytics and controls—allowing us to better forecast and understand what will happen and thus optimize process outcomes—is not only feasible but inevitable, according to Bonnie Shum, principal engineer, pharma technical innovation, technology & manufacturing sciences and technology at Genentech. “Well-trained artificial intelligence systems can help drive better decision making and how data is analyzed from drug discovery to process development and to manufacturing processes,” she says. Those advances, though, only really matter when they improve the lives of patients. That’s exactly what Shum expects. “The convergence of digital transformation and operational/processing changes will be critical for the facilities of the future and meeting the needs of our patients,” she continues. “Digital solutions may one day provide fully automated bioprocessing, eliminating manual intervention and enabling us to anticipate potential process deviations to prevent process failures, leading to real-time release and thus faster access for patients.” To turn Bioprocessing 4.0 into a production line for precision healthcare, real-time release and quickly manufacturing personalized medicines will be critical. Adding digitization and advanced analytics wherever possible will drive those improvements. In fact, many of these improvements, especially moving from descriptive to predictive bioprocessing, depend on more digitization.

Read More

Spotlight

Netcare

The Netcare Group operates the largest private hospital group, primary care network and medical emergency service in South Africa. Netcare is also the biggest private trainer of emergency personnel and healthcare workers. At Netcare, our inspiration to excel in providing medical innovation and quality care is to be found in our values. We continue to focus on living our core value of care, and the associated values of dignity, participation, truth and passion. Care at every level of our organisation is fundamental to Netcare's sustainability and our contribution to the countries in which we operate. It provides the reference point for all our people as we transform our businesses and seek to build bridges of trust with our patients, doctors and all other stakeholders.

Events